Back to today’s briefing

Story perspectives

Experts Urge Innovative Treatments for Marginal Zone Lymphoma

2/18/2025

46 6

Summary

Story summary

Andrew D. Zelenetz, MD, PhD, shed light on the daunting hurdles in treating marginal zone lymphoma (MZL), a rare and intricate disease. He pointed to the potential of innovative therapies like BTK inhibitors and CAR T-cell treatments, urging pharmaceutical companies to recognize MZL as a unique challenge to enhance patient care and outcomes.

1 of 1

Story summary

Andrew D. Zelenetz, MD, PhD, shed light on the daunting hurdles in treating marginal zone lymphoma (MZL), a rare and intricate disease. He pointed to the potential of innovative therapies like BTK inhibitors and CAR T-cell treatments, urging pharmaceutical companies to recognize MZL as a unique challenge to enhance patient care and outcomes.